Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2

Cell Cycle

Volumn 13, Issue 14, 2014, Pages 2296-2305

  Rastelli, Giulio ^a   Anighoro, Andrew ^a   Chripkova, Martina ^b,c   Carrassa, Laura ^b   Broggini, Massimo ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Allosteric inhibitors; BEAR; Cyclin dependent kinase 2; Protein kinase; Structure based drug design; Virtual screening

Indexed keywords

BAS 00111586; BAS 00380830; BAS 00381203; BAS 00434932; BAS 00590245; BAS 00619651; BAS 00631909; BAS 00916022; BAS 01060577; BAS 01060589; BAS 01123443; BAS 01404025; BAS 01547732; BAS 02102245; BAS 02102259; BAS 02102292; CYCLIN DEPENDENT KINASE 2 INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; LIGAND; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ALLOSTERISM; ALPHA HELIX; ARTICLE; BREAST CANCER CELL LINE; CELL GROWTH; CELL PROLIFERATION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG SCREENING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATIC ELECTRICITY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; COMPUTER AIDED DESIGN; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; FEMALE; IC50; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; PROTEIN SECONDARY STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER-AIDED DESIGN; CYCLIN-DEPENDENT KINASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904488820     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29295     Document Type: Article

References (41)

1. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39; PMID:19104514; http://dx.doi.org/10. 1038/nrc2559
2. Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol Ther 2011; 130:144-56; PMID:21256157; http://dx.doi.org/10.1016/j. pharmthera.2011.01.007
3. Palmieri L, Rastelli G. αC Helix Displacement as a General Approach for Protein Kinases Allosteric Modulation. Drug Discov Today 2013; 18:407-14; PMID:23195331; http://dx.doi.org/10.1016/j.drudis.2012.11.009
4. Rabiller M, Getlik M, Klüter S, Richters A, Tückmantel S, Simard JR, Rauh D. Proteus in the world of proteins: conformational changes in protein kinases. Arch Pharm (Weinheim) 2010; 343:193-206; PMID:20336692; http://dx.doi.org/10.1002/ardp.201000028
5. Lamba V, Ghosh I. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 2012; 18:2936-45; PMID:22571662; http://dx.doi.org/10.2174/138161212800672813
6. Fang Z, Grütter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem Biol 2013; 8:58-70; PMID:23249378; http://dx.doi.org/10.1021/cb300663j
7. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547-66; PMID:19568282; http://dx.doi.org/10. 1038/nrd2907
8. CDK Inhibitor Triples PFS in Breast Cancer. Cancer Discov 2013; 3:4
9. Russo AA, Jeffrey PD, Patten AK, Massagué J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382:325-31; PMID:8684460; http://dx.doi.org/10. 1038/382325a0
10. McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents 2003; 3:57-69; PMID:12678915; http://dx.doi.org/10.2174/1568011033353506
11. Andrews MJ, McInnes C, Kontopidis G, Innes L, Cowan A, Plater A, Fischer PM. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem 2004; 2:2735-41; PMID:15455144; http://dx.doi.org/10.1039/b409157d
12. Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, Barrett A, Aslanidi G, Cress WD, Law B. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J Biol Chem 2009; 284:29945-55; PMID:19710018; http://dx.doi.org/10.1074/jbc.M109.055251
13. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87; PMID:11960696
14. Echalier A, Endicott JA, Noble ME. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 2010; 1804:511-9; PMID:19822225; http://dx.doi.org/10.1016/j.bbapap.2009.10.002
15. Betzi S, Alam R, Martin M, Lubbers DJ, Han H, Jakkaraj SR, Georg GI, Schönbrunn E. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011; 6:492-501; PMID:21291269; http://dx.doi.org/10.1021/ cb100410m
16. Martin MP, Alam R, Betzi S, Ingles DJ, Zhu J-Y, Schönbrunn E. A novel approach to the discovery of small-molecule ligands of CDK2. Chembiochem 2012; 13:2128-36; PMID:22893598; http://dx.doi.org/10.1002/cbic.201200316
17. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785-91; PMID:19399780; http://dx.doi.org/ 10.1002/jcc.21256
18. Rastelli G, Del Rio A, Degliesposti G, Sgobba M. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 2010; 31:797-810; PMID:19569205
19. Degliesposti G, Portioli C, Parenti MD, Rastelli G. BEAR, a novel virtual screening methodology for drug discovery. J Biomol Screen 2011; 16:129-33; PMID:21084717; http://dx.doi.org/10.1177/1087057110388276
20. Sgobba M, Caporuscio F, Anighoro A, Portioli C, Rastelli G. Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations. Eur J Med Chem 2012; 58:431-40; PMID:23153814; http://dx.doi.org/10.1016/j.ejmech.2012.10.024
21. Degliesposti G, Kasam V, Da Costa A, Kang HK, Kim N, Kim DW, Breton V, Kim D, Rastelli G. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids. ChemMedChem 2009; 4:1164-73; PMID:19437467; http://dx.doi.org/10.1002/cmdc.200900111
22. Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM. Detection of allosteric kinase inhibitors by displacement of active site probes. J Biomol Screen 2012; 17:813-21; PMID:22453235; http://dx.doi.org/10.1177/ 1087057112439889
23. Simard JR, Getlik M, Grütter C, Schneider R, Wulfert S, Rauh D. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. J Am Chem Soc 2010; 132:4152-60; PMID:20201574; http://dx.doi.org/10.1021/ja908083e
24. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011; 10:197-208; PMID:21358739; http://dx.doi.org/10.1038/nrd3367
25. Rastelli G. Emerging topics in structure-based virtual screening. Pharm Res 2013; 30:1458-63; PMID:23468050; http://dx.doi.org/10.1007/s11095-013-1012-9
26. Schmitz NM, Leibundgut K, Hirt A. CDK2 catalytic activity and loss of nuclear tethering of retinoblastoma protein in childhood acute lymphoblastic leukemia. Leukemia 2005; 19:1783-7; PMID:16107892; http://dx.doi.org/10.1038/sj. leu.2403900
27. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-4; PMID:7877684; http://dx.doi.org/10.1038/374131a0
28. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131-49; PMID:12814430; http://dx.doi.org/10.1046/j.1365-2184.2003.00266.x
29. Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997; 29:559-73; PMID:9363633; http://dx.doi.org/10.1016/S1357-2725(96)00178-1
30. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012; 52:1757-68; PMID:22587354; http://dx.doi.org/10.1021/ci3001277
31. Case DA, Darden TE, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, et al. (2008), AMBER 10, University of California, San Francisco
32. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999; 17:57-61; PMID:10660911
33. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003; 24:1999-2012; PMID:14531054; http://dx.doi.org/10.1002/jcc.10349
34. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004; 25:1157-74; PMID:15116359; http://dx.doi.org/10.1002/jcc.20035
35. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000; 33:889-97; PMID:11123888; http://dx.doi.org/10.1021/ar000033j
36. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12; PMID:15264254; http://dx.doi.org/10. 1002/jcc.20084
37. Suite 2011: Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011
38. RDKit: Cheminformatics and Machine Learning Software. http://www.rdkit.org/
39. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform 2011; 3:33; PMID:21982300; http://dx.doi.org/10.1186/1758-2946-3-33
40. Suite 2011: QikProp, version 3.4, Schrödinger, LLC, New York, NY, 2011
41. Asinex; Asinex Ltd: Moscow; http://www.asinex.com